Emerging Pharmacologic Treatments for Alcohol-Associated Hepatitis: Current Status and Future Landscape.

Timothy R Morgan

Journal: Clinics in liver disease 2024;28(4):747-760

PMID: 39362719

Full Text on Elsevier Science View on PubMed

Abstract

Several treatments have shown efficacy in preliminary alcohol-associated hepatitis trials. Interleukin-22 improved Model of End-stage Liver Disease score and aminotransferases in a phase II trial. The endogenous cholesterol derivative, larsucosterol, improved outcomes in a multi-center United States or European phase II trial. The antioxidants N-acetylcysteine and metadoxine improved survival in large trials. Trials from India report improved survival with granulocyte-colony stimulating factor, as well as improved outcome among patients receiving fecal microbiota transfer. Translational studies suggest that phage treatment of cytolytic Enterococcus faecalis may reduce liver injury.

Published by Elsevier Inc.

Address: Medical Service/Gastroenterology, VA Long Beach Healthcare System, 5901 East Seventh Street, Long Beach, CA 90822, USA; Department of Medicine, University of California, Irvine, CA, USA. Electronic address: [email protected].

DOI: 10.1016/j.cld.2024.06.014

Link outs

Subscription / membership required

Full Text Sources:

MeSH Terms: Humans, Hepatitis, Alcoholic, Antioxidants, Interleukin-22, Acetylcysteine, Fecal Microbiota Transplantation, Granulocyte Colony-Stimulating Factor